Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 7—July 2016
Dispatch

Postbooster Antibodies from Humans as Source of Diphtheria Antitoxin

Jesús F. Bermejo-MartinComments to Author , Ana Avila-Alonso, Milagros González-Rivera, Eduardo Tamayo, Jose María Eiros, and Raquel Almansa
Author affiliations: Hospital Clínico Universitario de Valladolid, Valladolid, Spain (J.F. Bermejo-Martin, A. Avila-Alonso, E. Tamayo, J. María Eiros, R. Almansa); Hospital General Universitario Gregorio Marañón, Madrid, Spain (M. González-Rivera)

Main Article

Table

Seroepidemiologic studies assessing levels of antidiphtheria antibodies in adults who received a booster dose of vaccine*

Ref. Study population
Vaccine
Immunogenicity, GMC IU/mL (95% CI)
Mean age, y (SD or range) No. Before booster After booster
(8) 40.1 (13.63) 1,448 0.5 mL Tdap (Boostrix; GlaxoSmithKline Biologicals, Rixensart, Belgium) 0.4 (0.4–0.4) 4.7 (4.4–5.1)
40.4 (13.48) 728 0.5 mL Tdap (Adacel; Sanofi Pasteur, Swiftwater, PA, USA) 0.5 (0.4–0.5) 5.0 (4.6–5.4)
(9) 31.7 (15–69) 64 0.5 mL of Tdap (Sanofi Pasteur Limited, Toronto, ON, Canada) after previous vaccination with MCV4D (Menactra; Sanofi Pasteur, Swiftwater, PA, USA) 4.45 (2.77–7.15) 8.70 (6.59–11.5)
379 0.5 mL Tdap (Sanofi Pasteur Limited, Toronto) 0.13 (0.11–0.16) 2.17 (1.84–2.56)
(10) 19.4 (1.2) 55 0.2 mL DTap (Kaketsuke, Kumamoto, Japan) 0.22 (0.16–0.30) 4.29 (3.53–5.21)
19.4 (0.8) 56 0.5 mL DTap (Kaketsuke) 0.21 (0.15–0.30) 6.28 (4.86–8.11)
(11) 66.0 (59–91) 252 0.5 mL Tdap (Repevax; Sanofi Pasteur MSD GmbH, Leimen, Germany) 0.04 (0.03–0.06) 1.09 (0.81–1.46)
24.0 (20–33) 21 0.14 (0.05–0.33) 4.16 (2.36–7.34)
(12) 21.1 (0.31) 74 0.5 mL Tdap (Boostrix) 0.3 (0.2–0.4) 6.0 (4.7–7.7)
(13) 26.5 (18–52) 401 0.5 mL TdaP (Statens Serum Institut, Copenhagen, Denmark) 0.11 (0.9–0.14) 4.60 (4.03–5.26)
26.1 (18–55) 399 0.5 mL diTeBooster (Statens Serum Institut) 0.11 (0.09–0.14) 5.54 (4.00–5.15)

*DTaP, diphtheria, tetanus, and pertussis vaccine (for children >6 years of age); GMC, geometric mean concentration; Ref., reference; Tdap, tetanus, diphtheria, and pertussis vaccine (for children >11 years of age and adults).

Main Article

References
  1. European Centre for Disease Prevention and Control. Rapid risk assessment: a case of diphtheria in Spain [cited 2015 Jul 7]. http://ecdc.europa.eu/en/publications/Publications/diphtheria-spain-rapid-risk-assessment-june-2015.pdf
  2. Opinel  A, Tröhler  U, Gluud  C, Gachelin  G, Smith  GD, Podolsky  SH, Commentary: the evolution of methods to assess the effects of treatments, illustrated by the development of treatments for diphtheria, 1825–1918. Int J Epidemiol. 2013;42:662–76. DOIPubMedGoogle Scholar
  3. Wagner  KS, Stickings  P, White  JM, Neal  S, Crowcroft  NS, Sesardic  D, A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine. 2009;28:14–20. DOIPubMedGoogle Scholar
  4. Both  L, White  J, Mandal  S, Efstratiou  A. Access to diphtheria antitoxin for therapy and diagnostics. Euro Surveill. 2014;19:20830.
  5. Centers for Disease Control and Prevention. Use of diphtheria antitoxin (DAT) for suspected diphtheria cases [cited 2015 Aug 19]. http://www.cdc.gov/diphtheria/downloads/protocol.pdf
  6. Wagner  KS, White  JM, Andrews  NJ, Borrow  R, Stanford  E, Newton  E, Immunity to tetanus and diphtheria in the UK in 2009. Vaccine. 2012;30:7111–7. DOIPubMedGoogle Scholar
  7. Bissumbhar  B, Rakhmanova  AG, Berbers  GA, Iakolev  A, Nosikova  E, Melnick  O, Evaluation of diphtheria convalescent patients to serve as donors for the production of anti-diphtheria immunoglobulin preparations. Vaccine. 2004;22:1886–91. DOIPubMedGoogle Scholar
  8. Blatter  M, Friedland  LR, Weston  WM, Li  P, Howe  B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine. 2009;27:765–72. DOIPubMedGoogle Scholar
  9. Halperin  SA, McNeil  S, Langley  J, Blatter  M, Dionne  M, Embree  J, Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose. Vaccine. 2011;29:8459–65. DOIPubMedGoogle Scholar
  10. Hara  M, Okada  K, Yamaguchi  Y, Uno  S, Otsuka  Y, Shimanoe  C, Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan. Clin Vaccine Immunol. 2013;20:1799–804. DOIPubMedGoogle Scholar
  11. Kaml  M, Weiskirchner  I, Keller  M, Luft  T, Hoster  E, Hasford  J, Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006;24:6808–11 .DOIPubMedGoogle Scholar
  12. Mertsola  J, Van Der Meeren  O, He  Q, Linko-Parvinen  A, Ramakrishnan  G, Mannermaa  L, Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010;51:656–62. DOIPubMedGoogle Scholar
  13. Thierry-Carstensen  B, Jordan  K, Uhlving  HH, Dalby  T, Sørensen  C, Jensen  AM, A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine. 2012;30:5464–71. DOIPubMedGoogle Scholar
  14. Sutjita  M, Hohmann  A, Comacchio  R, Bradley  J. Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids. Clin Exp Immunol. 1988;73:191–7.PubMedGoogle Scholar
  15. Estabrook  MM, Jarvis  GA, McLeod Griffiss  J. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun. 2007;75:1025–33. DOIPubMedGoogle Scholar

Main Article

Page created: June 14, 2016
Page updated: June 14, 2016
Page reviewed: June 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external